

DES Daughters

Baird DD and Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. *Reprod Toxicol* May 2005;20(1):81-84.

Camp EA, Coker AL, Robboy SJ, Noller KL, Goodman KJ, Titus-Ernstoff LT, et al. Breast cancer screening in women exposed in utero to diethylstilbestrol. *J Womens Health* 01 Apr 2009;18(4):547-552.

Camp EA, Coker AL, Troisi R, Robboy SJ, Noller KL, Goodman KJ, et al. Cervical screening and general physical examination behaviors of women exposed in utero to diethylstilbestrol. *J Low Genit Tract Dis* Apr 2008;12(2):111-117.

Casey PM, Long ME, Marnach ML. Abnormal cervical appearance: what to do, when to worry? *Mayo Clinic Proceedings* 2011;86(2): 147-151.

CDC warns on DES drug risk to aging mothers and children. *Aging Today* 2003;24(2):1- 2.

D'Aloisio AA, Baird DD, DeRoo LA, Sandler DP. Association of intrauterine and early-life exposures with diagnosis of uterine leiomyomata by 35 years of age in the Sister Study. *Environ Health Perspect* 2010;118(3):375-381.

Dasanu CA and Herzog TJ. Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. *Medscape J Med* 2009;11(1):6.

DES exposure in utero linked to earlier menopause. *Contemporary OB/GYN* 2006;51(11):18-18.

DES Follow-up Study, Adverse health outcomes in women exposed in utero to diethylstilbestrol. *New Engl J Med* 2011.

DES ups daughter's breast cancer risk. *Health News (Waltham, Mass)* Nov 2006;12(11):10.

Doherty LF, Bromer JG, Zhou Y, Aldad TS, Taylor HS. In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: An epigenetic mechanism linking endocrine disruptors to breast cancer. *Horm Cancer* 2010;1(3):146-155.

Exposure in utero to DES. *ACOG Clin Rev* 2002;7(5):12.

Fickling D. Australia recognises cancer risk for "DES daughters". *Lancet* 19 Jun 2004;363(9426):2059.

Frank AW. DES daughters: Embodied knowledge and the transformation of women's health politics. *Social Health Ill* 2010;32(5):817-818.

Goodman A, Schorge J, Greene MF. The long-term effects of in utero exposures - The DES story. *New Engl J Med*. Apr 20 2011.

Greathouse KL, Cook JD, Lin K, Davis BJ, Berry TD, Bredfeldt TG, et al. Identification of uterine leiomyoma genes developmentally reprogrammed by neonatal exposure to diethylstilbestrol. *Reprod Sci* October 2008;15(8):765-778.

Hajek RA, King DW, Hernandez-Valero MA, Kaufman RH, Liang JC, Chilton JA, et al. Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero. *Int J Gynecol Cancer* Jan 2006;16(1):318-324.

Hall WB, Detterbeck FC, Livasy CA, Fowler Jr WC. Endobronchial clear cell adenocarcinoma occurring in a patient 15 years after treatment for DES-associated vaginal clear cell adenocarcinoma. *Gynecol Oncol* Jun 2004;93(3):708-710.

Hammes B and Laitman CJ. Diethylstilbestrol (DES) update: Recommendations for the identification and management of DES-exposed individuals. *J Midwifery Womens Health* 2003;48(1):19-29.

Hatch EE, Troisi R, Wise LA, Hyer M, Palmer JR, Titus-Ernstoff L, et al. Age at natural menopause in women exposed to diethylstilbestrol in utero. *Am J Epidemiol* Oct 2006;164(7):682-688.

Hatch EE, Troisi R, Wise LA, Titus-Ernstoff L, Hyer M, Palmer JR, et al. Preterm birth, fetal growth, and age at menarche among women exposed prenatally to diethylstilbestrol (DES). *Reprod Toxicol* 2011;31(2):151-157.

Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Chevillat AR, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. *New Engl J Med* 2011;365(14):1304-1314.

Hsu PY, Deatherage DE, Rodriguez BA, Liyanarachchi S, Weng YI, Zuo T, et al. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. *Cancer Res* 15 Jul 2009;69(14):5936-5945.

Huang WW, Yin Y, Bi Q, Chiang TC, Garner N, Vuoristo J, et al. Developmental diethylstilbestrol exposure alters genetic pathways of uterine cytodifferentiation. *Mol Endocrinol*. Mar 2005;19(3):669-682.

Ikeda Y, Tanaka H, Esaki M. Effects of gestational diethylstilbestrol treatment on male and female gonads during early embryonic development. *Endocrinology* August 2008;149(8):3970-3979.

Kurita T, Mills AA, Cunha GR. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. *Development* Apr 2004;131(7):1639-1649.

Lagiou P. Intrauterine factors and breast cancer risk. *Lancet Oncol* 2007 Dec;8(12):1088-100. *Lancet Oncol* 2007;8(12):1047-1048.

Laitman CJ. DES exposure and the aging woman: mothers and daughters. *Curr Womens Health Rep* Oct 2002;2(5):390-393.

Larson PS, Ungarelli RA, De Las Morenas A, Cupples LA, Rowlings K, Palmer JR, et al. In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium. *Cancer* 01 Nov 2006;107(9):2122-2126.

Lin LM, Sciubba DM, Gallia GL, Sosnowski J, Weingart JD. Diethylstilbestrol (DES)-induced clear cell adenocarcinoma of the vagina metastasizing to the brain. *Gynecol Oncol* Apr 2007;105(1):273-276.

Loutradis D, Stefanidis K, Kiapekou E, Zapanti E, Panitsa-Fafli C, Antsaklis A. Estradiol and progesterone supplementation during luteal phase improved the receptivity of the endometrium in a patient with a history of diethylstilboestrol exposure in-utero. *Hormones (Athens, Greece)* 2006;5(2):147-150.

Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis. *Trends Endocrinol Metabol* Sep 2009;20(7):357-363.

Mano MS, Kerr J, Kennedy J. Management of breast cancer in patients prenatally exposed to diethylstilbestrol: Are we prepared? *Breast* Oct 2005;14(5):408-410.

Matalliotakis IM, Cakmak H, Koukoura OG, Koumantakis GE, Sakkas D, Arici A. Endometriosis after in

utero exposure to DES: Presentation of case reports from the Yale patient series. *Int J Fertil Womens Med* 2008;53(4):125-129.

Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Michels KB, Hunter DJ. In utero exposures and the incidence of endometriosis. *Fertil Steril* Dec 2004;82(6):1501-1508.

Miyagawa S, Sato M, Iguchi T. Molecular mechanisms of induction of persistent changes by estrogenic chemicals on female reproductive tracts and external genitalia. *J Steroid Biochem Mol Biol* 2011;127(1-2):51-57.

Newbold RR. Developmental exposure to endocrine-disrupting chemicals programs for reproductive tract alterations and obesity later in life. *Am J Clin Nutr* 2011;94(6):1939S-1942S.

Newbold RR, Jefferson WN, Grissom SF, Padilla-Banks E, Snyder RJ, Lobenhofer EK. Developmental exposure to diethylstilbestrol alters uterine gene expression that may be associated with uterine neoplasia later in life. *Mol Carcinog* Sep 2007;46(9):783-796.

O'Reilly EJ, Mirzaei F, Forman MR, Ascherio A. Diethylstilbestrol exposure in utero and depression in women. *Am J Epidemiol* April 2010;171(8):876-882.

Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: Preliminary results (United States). *Cancer Causes Control* Oct 2002;13(8):753-758.

Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomarkers Prevent* Aug 2006;15(8):1509-1514

Pitkin RM, Herbst AL, Kurman RJ, Scully RE. Vaginal and cervical abnormalities after exposure to stilbestrol in utero. *Obstetrics and Gynecology* Aug 2003;102(2):222.

Porcu G, Courbiere B, Sakr R, Carcopino X, Gamberre M. Spontaneous rupture of a first-trimester gravid uterus in a woman exposed to diethylstilbestrol in utero: A case report. *J Reprod Med* 01 Sep 2003 48(9):744-746.

Prenatal DES exposure: Long-term somatic effects. *Prescrire International* 20(121):265.

Prenatal exposure to DES may increase breast cancer risk. *Mayo Clin Womens Healthsource* Jan 2007;11(1):3.

Psychological consequences of DES exposure in utero. *Prescrire International* 20(121):264-266.

Richardson MK. By the way, doctor. My mother took DES when she was pregnant with me. I'm now 69, my daughter is 41, and we've both had gynecological problems. What particular risks do we have because of our DES exposure, and what can we do about them? *Harv Womens Health Watch* May 2010;17(9):7.

Smith E, White MC, Weir HK, Peipins LA, Thompson TD. Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States. *Cancer Cause Control* 2012;23(1):207-211.

Steiner AZ, D'Aloisio AA, DeRoo LA, Sandler DP, Baird DD. Association of intrauterine and early-life exposures with age at menopause in the Sister Study. *Am J Epidemiol* 2010;172(2):140-148.

Stoll C, Alembik Y, Dott B. Limb reduction defects in the first generation and deafness in the second generation of intrauterine exposed fetuses to diethylstilbestrol. *Ann Genet* Oct 2003;46(4):459-465.

Strohsnitter W and Noller KL. Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol. *J Rheumatol* 2010;37(10): 2167-2173.

Study elucidates health risks for DES daughters. *Harvard Women's Health Watch* 19(4):7-7. Review of report from the DES Follow-up Study, Adverse health outcomes in women exposed in utero to diethylstilbestrol. *New Engl J Med* 2011.

Tedeschi CA, Rubin M, Krumholz BA. Six cases of women with diethylstilbestrol in utero demonstrating long-term manifestations and current evaluation guidelines. *J Low Genit Tract Dis* Jan 2005;9(1):11-18.

Titus-Ernstoff L, Perez K, Hatch EE, Troisi R, Palmer JR, Hartge P, et al. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol *Epidemiology (Cambridge, Mass.)* Mar 2003;14(2):155-160.

Titus-Ernstoff L, Troisi R, Hatch EE, Palmer JR, Hyer M, Kaufman, et al. Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). *Int J Androl* April 2010;33(2):377-383.

Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy S, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. *Int J Cancer* 15 Jul 2007;121(2):356-360.

Troisi R, Titus-Ernstoff L, Hyer M, Hatch EE, Robboy SJ, Strohsnitter W, et al. Preeclampsia risk in women exposed in utero to diethylstilbestrol. *Obstet Gynecol* Jul 2007;110(1):113-120.

Udry JR. Putting prenatal effects on sex-dimorphic behavior in perspective: an absolutely complete theory. *Epidemiology (Cambridge, Mass.)* Mar 2003;14(2):135-136.

Valle RF, Sankpal R, Marlow JL, Cohen L. Cervical stenosis: A challenging clinical entity. *J Gynecol Surg* Dec 2002;18(4):129-143.

Van Leeuwen FE, van Erp EJ, Helmerhorst TJ, Heintz PA. Compensation for diethylstilbestrol injury. *Lancet* 2007 Jan 20;369(9557):173-4.

Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM. Pseudoinfiltrative tubal metaplasia of the endocervix: A potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. *Int J Gynecol Pathol* Oct 2005;24(4):391-398.

Velemir L, Gallot D, Jardon K, Mage G, Pouly JL. Uterine rupture at 26 weeks after metroplasty for uterine enlargement in diethylstilbestrol-exposed uterus: A case report. *European J Obstet Gynecol Reprod Biol* Jun 2008;138(2):243-244.

Verdoux H, Ropers J, Costagliola D, Clavel-Chapelon F, Paoletti X. Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. *Psychol Med* Sep 2007;37(9):1315-1322.

Verloop J, Van Leeuwen FE, Helmerhorst TJM, Van Boven HH, Rookus MA. Cancer risk in DES daughters. *Cancer Causes Control* July 2010;21(7):999-1007.

Watanabe H, Suzuki A, Kobayashi M, Lubahn DB, Handa H, Iguchi T. Similarities and differences in uterine gene expression patterns caused by treatment with physiological and non-physiological estrogens. *J Mol Endocrinol* Dec 2003;31(3):487-497.

Wise LA, Palmer JR, Hatch EE, Troisi R, Titus-Ernstoff L, Herbst AL, et al. Secondary sex ratio among women exposed to diethylstilbestrol in utero. *Environ Health Perspect* Sep 2007;115(9):1314-1319.

Wise LA, Palmer JR, Rowlings K, Kaufman RH, Herbst AL, Noller KL, et al. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. *Obstet Gynecol* Jan 2005;105(1):167-173.

Xue F and Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. *Lancet Oncol* 2007;8(12):1088-1100.

Yin Y, Lin C, Ma L. Msx2 promotes vaginal epithelial differentiation and Wolffian duct regression and dampens the vaginal response to diethylstilbestrol. *Mol Endocrinol* 2006;20(7):1535-154.